Asthma

Q2 2025 saw more research emerge in asthma therapeutics and management as well as rarer pulmonary diseases.

June 2025 saw more research emerge in asthma therapeutics and management as well as rarer pulmonary diseases.

Discover how advancements in biologic therapies and precision medicine are transforming asthma and COPD management, enhancing patient care and outcomes.

Although limited, recent research has indicated overall positive results of dupilumab in both reducing severe exacerbations and lowering risk of control loss.

In this analysis, investigators highlight preferential options for the initial step-up of treatment among children with uncontrolled asthma on inhaled corticosteroids.

Phase 4 data highlight dupilumab’s superiority to omalizumab for all primary and secondary efficacy endpoints of CRSwNP, and in all asthma-related endpoints.

Systematic review and meta-analysis findings support recent guidelines advising against short-acting beta-agonist monotherapy for asthma management.

Discover how recent advancements in biologic therapies are transforming asthma and COPD management, emphasizing personalized care and improved patient outcomes.

Explore the latest advancements in biologic therapies for asthma and COPD discussed in a recent clinical forum highlighting personalized medicine and biomarker-driven strategies for improved patient outcomes.

Discover the latest advancements in pulmonology, including innovative treatments for asthma, COPD, and pulmonary sarcoidosis, showcased at ATS 2025.

This Q&A interview highlights reductions observed in the use of rilzabrutinib for asthma symptom relief in a recent phase 2 study.

During her ATS interview, Lisa Wood, PhD, spoke about economic and geographic disparities and their connection to diet and related respiratory health outcomes.

This ATS interview features Lisa Wood, PhD, discussing recent findings related to childhood dietary intake and its connection to respiratory health.

View conference highlights from HCPLive’s coverage of the American Thoracic Society (ATS) International Conference 2025.

Findings from a post hoc analysis of the phase 3 DIRECTION study highlight tezepelumab’s consistent benefit on asthma exacerbations across trigger categories.

At ATS 2025, these data highlight a potential connection between asthma development and prenatal exposure to microplastics and other forms of pollution.

The approval adds to Ritestar’s currently approved albuterol sulfate 2.5 mg/3 mL (0.083%), 1.25 mg/3 mL, and 0.63 mg/3 mL strength products.

Results highlight dupilumab’s real-world benefit for asthma control in patients with and without coexisting chronic rhinosinusitis and/or nasal polyposis.

This analysis highlights rademikibart’s effect on blood eosinophil counts in those with asthma, exploring whether there was an IL-4Rα class effect.

The ProVENT data highlight dupilumab’s efficacy in treating severe asthma, with improvements in control, quality of life, and exacerbations being observed.

In this analysis, investigators found consistent benefits over placebo among children with type 2 asthma treated with dupilumab, regardless of condition length.

Long-term studies reveal that benralizumab achieves sustained remission in severe eosinophilic asthma, significantly reducing exacerbations in older adults.

Explore innovative strategies for asthma management that prioritize shared decision-making and address environmental, social, and behavioral factors.

A recent study reveals that asthma-COPD overlap does not significantly worsen outcomes in well-managed severe asthma patients.